Search clinical trials for: TMC435 (F021)

Total 165 results

Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C119 - A Study Comparing 2 New Capsule Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Respective Blood Levels of TMC435 Following Single Dose Administration

Hepatitis C Virus
Janssen R&D Ireland

Completed

A Study to Assess Bioavailability & Food Effect of Different Liquid and Capsule Formulations of TMC435.

Healthy Volunteers

United Kingdom
BioLineRx, Ltd.

Terminated

A Study Intended to Evaluate Safety, Tolerability and Pharmacokinetics (PK) Parameters of BL-1021

Healthy | Volunteers

Israel
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C116 - Relative Bioavailability and Food Effect Study

Hepatitis C
Janssen Research & Development, LLC

Completed

A Study to Examine the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of TMC435 in Healthy Chinese Participants

Healthy

China
Addpharma Inc.

Completed

Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022

Hypertension, Essential | Primary Hypercholesterolemia

Korea, Republic of
M. Arkin 1999 Ltd.
Vyne Therapeutics Inc.

Completed

Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients

Acne Vulgaris

Israel
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents TMC278 and Tenofovir

Hepatitis C Virus
Tolerion, Inc.

Withdrawn

Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN) (DAWN)

Diabetes Mellitus, Type 1

United States
Tolerion, Inc.

Withdrawn

Diabetes AutoimmunitY Withdrawn in Established Patients (DAY) (DAY)

Diabetes Mellitus, Type 1
Novo Nordisk A/S

Terminated

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects (explorer™2)

Healthy | Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United Kingdom, France, Germany
Novo Nordisk A/S

Completed

Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Arcturus Therapeutics, Inc.

Completed

Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects

SARS-CoV-2

Singapore
Tolerion, Inc.

Active, not recruiting

Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients (SUNRISE)

Diabetes Mellitus, Type 1

United States
Arcturus Therapeutics, Inc.

Terminated

Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021

SARS-CoV-2

Singapore
Elevation Oncology

Recruiting

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Neoplasms | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasm | Pancreas Neoplasm | Stomach Neoplasm

United States, Japan
Janssen R&D Ireland

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

Healthy

United States
University Medicine Greifswald

Active, not recruiting

Adaptive Immune Response to Seasonal Influenza Vaccination (AIGI) ((AIGI))

Seasonal Influenza Vaccination

Germany
Novo Nordisk A/S

Completed

Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Travere Therapeutics, Inc.

Recruiting

A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN (SPARTACUS)

Immunoglobulin A Nephropathy

United States, Hong Kong
Duramed Research

Completed

Open-Label Study to Evaluate the Safety and Efficacy of a Low-Dose 28-Day Oral Contraceptive

Contraception

United States
Janssen R&D Ireland

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients (RESTORE)

Hepatitis C

France, Belgium
Tibotec Pharmaceuticals, Ireland

Completed

TMC435 HPC1004 - Phase I Study Investigating the Pharmacokinetics of TMC435 in Healthy Chinese Volunteers

Hepatitis C

Hong Kong
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435

Hepatitis C Virus

United States
Arcturus Therapeutics, Inc.

Terminated

A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults

Covid19 | Corona Virus Infection | SARS-CoV Infection

United States, Singapore
Janssen R&D Ireland

Completed

A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male Patients

Healthy Male Participants

Belgium
Novo Nordisk A/S

Completed

Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B (Explorer 1)

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Austria, Sweden, Spain, Switzerland, United Kingdom, Germany, Malaysia, Denmark, South Africa, Thailand, Italy
Tibotec Pharmaceuticals, Ireland

Completed

A Study to Assess the Anti-viral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 in Participants Infected With Hepatitis C-Virus (HCV)

Hepatitis C

Belgium, Germany, Thailand
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C121: A Study Comparing 2 Tablet Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Effect of Food on Blood Levels of TMC435

Hepatitis C Virus
Janssen R&D Ireland

Completed

A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

Hepatitis C

United States, Australia, France, Ukraine, United Kingdom, Belgium, Germany, Spain, Israel, Portugal, Bulgaria, Netherlands, Canada, New Zealand, Russian Federation, Argentina, Brazil, Puerto Rico, Austria, Poland, Romania, Mexico
Ansun Biopharma, Inc.

Completed

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection (PIV)

Parainfluenza

United States
Ansun Biopharma, Inc.

Completed

Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza

Influenza

United States
Ansun Biopharma, Inc.

Completed

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen (DAS181-2-05)

Parainfluenza

United States
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435

Hepatitis C Virus

Czech Republic
Travere Therapeutics, Inc.

Completed

Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension

Healthy Subjects

United Kingdom
Hoffmann-La Roche

Recruiting

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

Alzheimers Disease

Korea, Republic of, United States, Poland, Canada, Spain, Australia, Japan, Chile, United Kingdom
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir

Hepatitis C Virus

Germany
Janssen Research & Development, LLC

Completed

A Pharmacokinetic Study to Assess the Effect of Food in Healthy Male Participants Receiving TMC435

Healthy

Japan
Johns Hopkins University
Under Armour, Inc.

Terminated

Reducing Breast Cancer-related Fatigue and Improving Cognition With Non-Invasive Brain Stimulation

Breast Cancer | Fatigue | Cognitive Dysfunction

United States
Travere Therapeutics, Inc.

Recruiting

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases (EPPIK)

Focal Segmental Glomerulosclerosis | Immunoglobulin A Nephropathy | Minimal Change Disease | Alport Syndrome | IgA Vasculitis

United States, Italy, Netherlands, Poland, Spain, United Kingdom, Germany, Sweden
University of Leicester
Travere Therapeutics, Inc.

Active, not recruiting

A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy (SPARTAN)

Immune System Diseases | Autoimmune Diseases | Kidney Diseases | Glomerulonephritis | Immunoglobulin A Nephropathy | Glomerulonephritis, IGA

United Kingdom
vTv Therapeutics

Completed

Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss

Obesity

United States, Canada
French Society for Intensive Care

Completed

Evaluation of the Sanitary Safety of a Healthcare Professional Conference Held 9-11 June 2021 in Paris (COVID-FREE)

Covid19

France
Janssen R&D Ireland

Completed

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection

Chronic Hepatitis C | Genotype 4 Chronic Hepatitis C

Spain
University Hospital of North Norway
Stiftelsen Helse og Rehabilitering

Completed

Transcranial Direct Current Stimulation (tDCS) as Treatment Method for Pain in Fibromyalgia

Fibromyalgia

Norway
Ansun Biopharma, Inc.
National Institutes of Health (NIH)

Completed

A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis (DAS181)

Bronchiectasis | Asthma

United States
Janssen R&D Ireland

Completed

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy (ATTAIN)

Hepatitis C

United States, Australia, France, Poland, United Kingdom, Germany, Spain, Belgium, Israel, Portugal, Bulgaria, Romania, Denmark, Greece, Sweden, Canada, Czech Republic, Argentina, Brazil, Austria, Hungary, Switzerland, Puerto Rico, No...
Tibotec Pharmaceuticals, Ireland

Completed

TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients

Hepatitis C

Belgium
Medical University of South Carolina
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells

Diabetes Mellitus, Type 1

United States
Tibotec Pharmaceuticals, Ireland

Completed

A Study in Healthy Female Participants Investigating the Effect of TMC435 on the Pharmacokinetics of the Synthetic Hormones of the Oral Contraceptive Ovysmen

Hepatitis C Virus

Belgium

3

Subscribe